Friederike Hörster1, Stefan Kölker2, J Gerard Loeber3, Martina C Cornel4, Georg F Hoffmann2, Peter Burgard2. 1. Division of Neuropediatrics and Inherited Metabolic Diseases, Department of General Pediatrics, University Children's Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany. friederike.hoerster@med.uni-heidelberg.de. 2. Division of Neuropediatrics and Inherited Metabolic Diseases, Department of General Pediatrics, University Children's Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany. 3. International Society for Neonatal Screening, Bilthoven, The Netherlands. 4. Clinical Genetics and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND: The state of newborn screening (NBS) programmes for organic acidurias in Europe was assessed by a web-based questionnaire in the EU programme of Community Action in Public Health 2010/2011 among the - at that time - 27 EU member states, candidate countries, potential candidates and three EFTA countries. RESULTS: Thirty-seven data sets from 39 target countries were analysed. Newborn screening for glutaric aciduria type I (GA-I) was performed in ten, for isovaleric aciduria (IVA) in nine and for methylmalonic aciduria including cblA, cblB, cblC and cblD (MMACBL) as well as for propionic aciduria (PA) in seven countries. Samples were obtained at a median age of 2.5 days and laboratory analysis began at median age of 4.5 days. Positive screening results were mostly confirmed in specialised centres by analysis of organic acids in urine. Confirmation of a positive screening result usually did not start before the second week of life (median ages: 9.5 days [IVA], 9 days [GA-I], 8.5 days [PA, MMACBL]) and was completed early in the third week of life (median ages: 15 days [IVA, PA, MMA], 14.5 days [GA-I]). Treatment was initiated in GA-I and IVA at a median age of 14 days and in MMACBL and PA at a median age of 15 days. CONCLUSION: NBS for organic acidurias in Europe is variable and less often established than for amino acid disorders. While for GA-I its benefit has already been demonstrated, there is room for debate of NBS for IVA and especially PA and MMACBL.
BACKGROUND: The state of newborn screening (NBS) programmes for organic acidurias in Europe was assessed by a web-based questionnaire in the EU programme of Community Action in Public Health 2010/2011 among the - at that time - 27 EU member states, candidate countries, potential candidates and three EFTA countries. RESULTS: Thirty-seven data sets from 39 target countries were analysed. Newborn screening for glutaric aciduria type I (GA-I) was performed in ten, for isovaleric aciduria (IVA) in nine and for methylmalonic aciduria including cblA, cblB, cblC and cblD (MMACBL) as well as for propionic aciduria (PA) in seven countries. Samples were obtained at a median age of 2.5 days and laboratory analysis began at median age of 4.5 days. Positive screening results were mostly confirmed in specialised centres by analysis of organic acids in urine. Confirmation of a positive screening result usually did not start before the second week of life (median ages: 9.5 days [IVA], 9 days [GA-I], 8.5 days [PA, MMACBL]) and was completed early in the third week of life (median ages: 15 days [IVA, PA, MMA], 14.5 days [GA-I]). Treatment was initiated in GA-I and IVA at a median age of 14 days and in MMACBL and PA at a median age of 15 days. CONCLUSION:NBS for organic acidurias in Europe is variable and less often established than for amino acid disorders. While for GA-I its benefit has already been demonstrated, there is room for debate of NBS for IVA and especially PA and MMACBL.
Entities:
Keywords:
Europe; Glutaric aciduria type I; Isovaleric aciduria; Methylmalonic acidurias; Newborn screening; Propionic aciduria; cblA, cblB, cblC and cblD
Authors: Ma Luz Couce; Daisy E Castiñeiras; Ma Dolores Bóveda; Ana Baña; José A Cocho; Agustín J Iglesias; Cristobal Colón; José R Alonso-Fernández; José M Fraga Journal: Mol Genet Metab Date: 2011-09-22 Impact factor: 4.797
Authors: Jana Heringer; S P Nikolas Boy; Regina Ensenauer; Birgit Assmann; Johannes Zschocke; Inga Harting; Thomas Lücke; Esther M Maier; Chris Mühlhausen; Gisela Haege; Georg F Hoffmann; Peter Burgard; Stefan Kölker Journal: Ann Neurol Date: 2010-11 Impact factor: 10.422
Authors: Stefan Kölker; Sven F Garbade; Cheryl R Greenberg; James V Leonard; Jean-Marie Saudubray; Antonia Ribes; H Serap Kalkanoglu; Allan M Lund; Begoña Merinero; Moacir Wajner; Mónica Troncoso; Monique Williams; John H Walter; Jaume Campistol; Milagros Martí-Herrero; Melissa Caswill; Alberto B Burlina; Florian Lagler; Esther M Maier; Bernd Schwahn; Aysegul Tokatli; Ali Dursun; Turgay Coskun; Ronald A Chalmers; David M Koeller; Johannes Zschocke; Ernst Christensen; Peter Burgard; Georg F Hoffmann Journal: Pediatr Res Date: 2006-04-26 Impact factor: 3.756
Authors: Federica Deodato; Sara Boenzi; Filippo M Santorelli; Carlo Dionisi-Vici Journal: Am J Med Genet C Semin Med Genet Date: 2006-05-15 Impact factor: 3.908
Authors: Regina Ensenauer; Ralph Fingerhut; Esther M Maier; Roman Polanetz; Bernhard Olgemöller; Wulf Röschinger; Ania C Muntau Journal: Clin Chem Date: 2011-02-18 Impact factor: 8.327
Authors: Stefan Kölker; Sven F Garbade; Nikolas Boy; Esther M Maier; Thomas Meissner; Chris Mühlhausen; Julia B Hennermann; Thomas Lücke; Johannes Häberle; Jochen Baumkötter; Wolfram Haller; Edith Muller; Johannes Zschocke; Peter Burgard; Georg F Hoffmann Journal: Pediatr Res Date: 2007-09 Impact factor: 3.756
Authors: Stefan Kölker; Ernst Christensen; James V Leonard; Cheryl R Greenberg; Avihu Boneh; Alberto B Burlina; Alessandro P Burlina; Marjorie Dixon; Marinus Duran; Angels García Cazorla; Stephen I Goodman; David M Koeller; Mårten Kyllerman; Chris Mühlhausen; Edith Müller; Jürgen G Okun; Bridget Wilcken; Georg F Hoffmann; Peter Burgard Journal: J Inherit Metab Dis Date: 2011-03-23 Impact factor: 4.982
Authors: Péter Monostori; Glynis Klinke; Sylvia Richter; Ákos Baráth; Ralph Fingerhut; Matthias R Baumgartner; Stefan Kölker; Georg F Hoffmann; Gwendolyn Gramer; Jürgen G Okun Journal: PLoS One Date: 2017-09-15 Impact factor: 3.240
Authors: Álvaro Martín-Rivada; Laura Palomino Pérez; Pedro Ruiz-Sala; Rosa Navarrete; Ana Cambra Conejero; Pilar Quijada Fraile; Ana Moráis López; Amaya Belanger-Quintana; Elena Martín-Hernández; Marcello Bellusci; Elvira Cañedo Villaroya; Silvia Chumillas Calzada; María Teresa García Silva; Ana Bergua Martínez; Sinziana Stanescu; Mercedes Martínez-Pardo Casanova; Miguel L F Ruano; Magdalena Ugarte; Belén Pérez; Consuelo Pedrón-Giner Journal: JIMD Rep Date: 2022-01-27
Authors: Hanneke A Haijes; Femke Molema; Mirjam Langeveld; Mirian C Janssen; Annet M Bosch; Francjan van Spronsen; Margot F Mulder; Nanda M Verhoeven-Duif; Judith J M Jans; Ans T van der Ploeg; Margreet A Wagenmakers; M Estela Rubio-Gozalbo; Martijn C G J Brouwers; Maaike C de Vries; Janneke G Langendonk; Monique Williams; Peter M van Hasselt Journal: J Inherit Metab Dis Date: 2019-12-22 Impact factor: 4.982